US scientists have figured out how to turn the tumor into a cancer vaccine factory and take advantage of it to destroy the tumor in the body.
The drug researched by Icahn Medical School in Mount Sinai, New York (USA) has been successful in the first clinical trial in non-Hodgkin's lymphoma patients - a type of immune system cancer , according to the article. Newly published in the scientific journal Nature.
Scientists have injected directly into the tumor itself an immune stimulant. The dose turned this tumor into a "vaccine factory" , which constantly recruited a form of immune cells called dendritic cells. After that, the tumor underwent low-dose radiation therapy, to be re-injected with a second immune stimulant, to help the tumor have the ability to "train" the dendritic cells that have been able to adequately wipe out "child" tumor throughout the patient's body.
The study has been successful in small-scale clinical trials in 11 patients with non-Hodgkin's lymphoma who are close to death and some patients who have completely relieved within months, even years.
According to Dr. Joshua Brody, director of the lymphoma immune therapy program at Tisch Cancer Institute, the national cancer research unit of the Icahn School of Medicine - the lead author of the project, this method works like a vaccine in place and has a wide meaning for many types of cancer.
Previously, it proved to be very effective in animal testing, 3 times more powerful than immunosuppressive and tumor control methods.
In the near future, doctors will test more clinically in many patients with lymphoma, breast cancer, head and neck cancer. Several lab tests are also being initiated for liver and ovarian cancer.